Tender Offer - Regulus Therapeutics Inc.
Form Type: SC14D9C
Filing Date: 2025-04-30
Corporate Action: Tender-offer
Type: New
Accession Number: 000119312525105857
Filing Summary: Regulus Therapeutics Inc. filed the SC14D9C, a Solicitation/Recommendation Statement, on April 30, 2025. The filing indicates that it relates solely to preliminary communications made prior to the commencement of a tender offer. The document incorporates information under Items 1.01, 5.02, 8.01, and 9.01 from a Current Report on Form 8-K also filed on the same date. Joseph P. Hagan serves as the CEO, with contact details provided for notices and communications.
Additional details:
Name Of Subject Company: Regulus Therapeutics Inc.
Name Of Person Filing Statement: Regulus Therapeutics Inc.
Title Of Class Of Securities: Common Stock, $0.001 par value per share
Cusip Number Of Common Stock: 75915K309
Contact Person Name: Joseph P. Hagan
Contact Person Address: 4224 Campus Point Court, Suite 210 San Diego, CA 92121
Contact Person Phone: (858) 202-6300
Law Firm Name: Latham & Watkins LLP
Law Firm Address: 650 Town Center Drive, 20th Floor Costa Mesa, California 92626
Law Firm Phone: (714) 540-1235
Comments
No comments yet. Be the first to comment!